The Pharmacy Times® Breast Cancer resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
What can we help you find?
According to study findings published in Cancer, mammography screenings reduce the rates of advanced and fatal cancers by more than 40%.
The anti-cancer medicine venetoclax may improve the current therapy for estrogen receptor-positive (ER+) breast cancer.
Study Finds High Adherence Rates, Low Adverse Effects Among Breast Cancer Patients Taking CDK 4/6 Inhibitors
Although the average wholesale price of the agents is more than $13,000, the investigators found that 9% of patients had a 0% co-pay throughout the 6-month period.
A community pharmacy-based intervention program was utilized to enhance AET adherence.
Sacituzumab govitecan-hziy, approved by the FDA on April 22, 2020, is the first in its class to treat metastatic, triple-negative breast cancer in patients who have received at least 2 prior therapies for metastatic disease.
Impact of Pharmacist Management of Oral Chemotherapy for Patients in an Outpatient Breast Cancer Clinic
In outpatient breast cancer clinics, oral chemotherapies are becoming more common for various malignancies, but hematologic and non-hematologic toxicities can cause challenges for patients.
According to the investigators, the cells are called ductal macrophages and function by consuming dying milk-producing cells, which need to be cleared away after milk production stops.
Study: Innovative Active Learning Increases Confidence, Knowledge of Pharmacists Managing CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer
The objective of the study was to develop an education program that increased confidence and knowledge of pharmacists managing CDK4/6 inhibitors.
In the oral chemotherapy setting, pharmacist care exceeded patients’ expectations and helped manage and avoid adverse events (AEs).
Researchers have developed a new way to map the molecules on tumor cells that flag their presence to the immune system.
The findings are part of the I-SPY clinical trial and were presented at the American Association for Cancer Research virtual annual meeting.
Study: Association of Patient Demographic Characteristics, Insurance Status With Survival in Cancer Patients
The objective of the study was to examine whether positive treatment effects in cancer randomized clinical trials apply to specific demographic or insurance subgroups.